Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea · Delayed Price · Currency is KRW 5,070.00
-90.00 (-1.74%)
Last updated: Aug 21, 2026, 3:00 PM KST
Kyongbo Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 121,208 | 137,943 | 148,701 | 200,579 | 239,069 | 256,999 | |
Market Cap Growth | 2.22% | -7.23% | -25.86% | -16.10% | -6.98% | -34.25% |
Enterprise Value | 265,380 | 257,424 | 236,571 | 278,339 | 290,819 | 317,767 |
Last Close Price | 5070.00 | 5770.00 | 6166.38 | 8261.77 | 9788.34 | 10462.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.03 | 756.70 | 32.05 | 67.44 | 391.54 | - |
PS Ratio | 0.43 | 0.52 | 0.62 | 0.93 | 1.22 | 1.51 |
PB Ratio | 0.82 | 0.95 | 1.02 | 1.39 | 1.66 | 1.76 |
P/TBV Ratio | 0.85 | 0.97 | 1.05 | 1.43 | 1.70 | 1.81 |
P/FCF Ratio | - | - | - | - | - | 556.60 |
P/OCF Ratio | 10.14 | 18.50 | 997.21 | 41.41 | 23.61 | 14.30 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.95 | 0.98 | 0.99 | 1.29 | 1.48 | 1.86 |
EV/EBITDA Ratio | 12.69 | 15.39 | 10.35 | 16.14 | 21.82 | 51.82 |
EV/EBIT Ratio | 39.03 | 73.16 | 22.63 | 50.20 | 208.82 | - |
EV/FCF Ratio | - | - | - | - | - | 688.22 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.08 | 0.87 | 0.63 | 0.53 | 0.45 | 0.39 |
Debt / EBITDA Ratio | 9.44 | 7.57 | 4.00 | 4.40 | 4.84 | 9.23 |
Debt / FCF Ratio | - | - | - | - | - | 122.55 |
Net Debt / Equity Ratio | 0.98 | 0.81 | 0.58 | 0.49 | 0.40 | 0.36 |
Net Debt / EBITDA Ratio | 8.61 | 7.09 | 3.73 | 4.09 | 4.30 | 8.53 |
Net Debt / FCF Ratio | -3.28 | -3.48 | -6.80 | -14.56 | -20.86 | 113.26 |
Asset Turnover | 0.82 | 0.88 | 0.87 | 0.85 | 0.82 | 0.70 |
Inventory Turnover | 2.01 | 1.89 | 1.85 | 2.40 | 2.65 | 2.27 |
Quick Ratio | 0.44 | 0.49 | 0.44 | 0.53 | 0.61 | 0.59 |
Current Ratio | 0.88 | 1.08 | 1.15 | 1.15 | 1.22 | 1.25 |
Return on Equity (ROE) | 3.49% | 0.13% | 3.19% | 2.07% | 0.42% | -4.97% |
Return on Assets (ROA) | 0.48% | 0.73% | 2.38% | 1.37% | 0.36% | -1.69% |
Return on Invested Capital (ROIC) | 0.78% | 0.58% | 4.43% | 2.67% | 0.70% | -3.34% |
Return on Capital Employed (ROCE) | 1.50% | 2.00% | 6.90% | 3.70% | 1.00% | -4.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.16% | 0.13% | 3.12% | 1.48% | 0.26% | -2.92% |
FCF Yield | -36.28% | -24.71% | -8.44% | -2.42% | -1.15% | 0.18% |
Payout Ratio | 23.69% | 655.72% | 25.77% | 40.19% | 195.77% | - |
Buyback Yield / Dilution | 0.09% | 0.03% | -0.03% | -1.80% | 1.62% | 0.25% |